https://www.selleckchem.com/pr....oducts/fenebrutinib-
Sedation (38%), language impairment (19%), challenging behaviour (10%), mild rash (10%) and dizziness (10%) were the commonest AEs. The responder rate was 40%, eight patients (9%) became seizure free. We found CGI-I to be dose-dependent. Regarding changes in body weight, we observed no difference between patients continuing or withdrawing ZNS therapy and responders or non-responders. Though, we identified older age as a significant risk factor for weight loss. Zonisamide may provide a safe and efficient therapeutic option
Beğen
Yorum Yap
Paylaş
